Selvedge Venture

Oxford Medical Products is focused on developing an innovative gastro-retentive hydrogel technology aimed at addressing weight loss challenges. The company has created a self-expanding capsule that occupies space in the stomach, effectively reducing hunger and promoting significant weight loss. This technology is designed to expand rapidly upon ingestion, providing a lasting feeling of satiety. Over time, the capsule breaks down gradually and passes naturally through the digestive system. Comprising a team of scientists, medical professionals, and entrepreneurs, Oxford Medical Products is dedicated to providing a safe, effective, and affordable solution to one of the world's pressing health issues.

Operator of an artificial intelligence-driven drug discovery (AIDD) based precision medicine company intended to address metabolic syndrome-related diseases. The company's platform applies systems biology to discover therapeutics and diagnostics for treating metabolic syndrome patients, it combines integrated multi-omics analysis and computational systems biology modeling with targeted wet laboratory experiments to originate novel precision therapeutic concepts that commercialize via partnerships with established biopharma companies, enabling diagnostic companies to get access to new therapeutic and diagnostic research and development programs for subsequent co-developmentmore

Sanome is focused on the development of innovative diagnostic products that utilize various biomarkers for early disease detection and prevention. By combining artificial intelligence with biophysical indicators, the company aims to create engaging and accurate in vitro diagnostic (IVD) tools. These tools are designed to facilitate novel at-home testing solutions, making healthcare more accessible to a broader population. Additionally, Sanome's predictive analytics platform offers clinical insights that support healthcare decision-making, enabling providers to identify potential health issues before they escalate. This approach not only enhances patient outcomes but also improves the overall efficiency of healthcare delivery.

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.

Oxford Medical Products is focused on developing an innovative gastro-retentive hydrogel technology aimed at addressing weight loss challenges. The company has created a self-expanding capsule that occupies space in the stomach, effectively reducing hunger and promoting significant weight loss. This technology is designed to expand rapidly upon ingestion, providing a lasting feeling of satiety. Over time, the capsule breaks down gradually and passes naturally through the digestive system. Comprising a team of scientists, medical professionals, and entrepreneurs, Oxford Medical Products is dedicated to providing a safe, effective, and affordable solution to one of the world's pressing health issues.

Exogene is a biotechnology company focused on advancing T-cell receptor (TCR)-based cancer immunotherapies for solid tumors. By integrating deep learning with high-throughput TCR-antigen screening, Exogene aims to efficiently identify new tumor targets that are common among cancer patients. The company is developing a computational platform designed to discover effective and safe TCRs against these targets, facilitating their therapeutic application. This innovative approach allows for the rapid and cost-effective development of TCR-based immunotherapies, ultimately supporting healthcare providers in creating cell therapies that enhance the immune system's ability to combat cancer.